Literature DB >> 6716582

A totally implanted injection port system for blood sampling and chemotherapy administration.

J W Gyves, W D Ensminger, J E Niederhuber, T Dent, S Walker, S Gilbertson, E Cozzi, P Saran.   

Abstract

We evaluated a totally implanted system consisting of a subcutaneous injection port connected to a silicone elastomer central venous catheter for vascular access, including blood drawing, in 35 patients with cancer. All patients lacked peripheral venous access sites and were undergoing aggressive chemotherapy programs. The cumulative duration of successful access exceeded 2,900 days (for individual patients: range, five to 203 days; median, 61 days). In no instance were infusions or injections unsuccessful. Blood-sampling attempts were successful 90% of the time. The system did not require flushing between uses, being filled with heparinized saline after each entry. There were no instances of irreversible catheter occlusion or shear and no system-related infections. Thus, this device appears to have advantages over other central venous catheters in terms of patient acceptance and lack of maintenance between uses.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6716582

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  13 in total

1.  Persistent left superior vena cava: a reason for pseudodisplacement of a port catheter.

Authors:  L Schiffmann; M Kruschewski; F Wacker; H J Buhr
Journal:  Surg Radiol Anat       Date:  2003-04-03       Impact factor: 1.246

2.  epic3: national evidence-based guidelines for preventing healthcare-associated infections in NHS hospitals in England.

Authors:  H P Loveday; J A Wilson; R J Pratt; M Golsorkhi; A Tingle; A Bak; J Browne; J Prieto; M Wilcox
Journal:  J Hosp Infect       Date:  2014-01       Impact factor: 3.926

3.  Venographic surveillance of tunneled venous access devices in adult oncology patients.

Authors:  M K Horne; D J May; H R Alexander; E P Steinhaus; E D Whitman; R C Chang; J L Doppman
Journal:  Ann Surg Oncol       Date:  1995-03       Impact factor: 5.344

4.  Morbidity using subcutaneous ports and efficacy of vancomycin flushing in cancer.

Authors:  H Rubie; M Juricic; S Claeyssens; A Krimou; J Lemozy; P Izard; J Guitard; M Ane; M F Prere; F Fedacou
Journal:  Arch Dis Child       Date:  1995-04       Impact factor: 3.791

5.  Immune-complex glomerulonephritis associated with Staphylococcus aureus infection of a totally implantable venous device.

Authors:  M Pulik; F Lionnet; P Genet; C Petitdidier; B Vacher
Journal:  Support Care Cancer       Date:  1995-09       Impact factor: 3.603

6.  epic2: National evidence-based guidelines for preventing healthcare-associated infections in NHS hospitals in England.

Authors:  R J Pratt; C M Pellowe; J A Wilson; H P Loveday; P J Harper; S R L J Jones; C McDougall; M H Wilcox
Journal:  J Hosp Infect       Date:  2007-02       Impact factor: 3.926

7.  Analysis of risk factors for central venous port failure in cancer patients.

Authors:  Ching-Chuan Hsieh; Hsu-Huei Weng; Wen-Shih Huang; Wen-Ke Wang; Chiung-Lun Kao; Ming-Shian Lu; Chia-Siu Wang
Journal:  World J Gastroenterol       Date:  2009-10-07       Impact factor: 5.742

8.  A new injection portal for brachially inserted central venous catheter. A multicenter study.

Authors:  H Starkhammar; M Bengtsson; T B Gain; W Galen; L Håkansson; J Hirsch; B Loggie; E S Schuman; J M Sterchi
Journal:  Med Oncol Tumor Pharmacother       Date:  1990

9.  Lack of experimental vesicant activity for the anticancer agents cisplatin, melphalan, and mitoxantrone.

Authors:  R T Dorr; D S Alberts; M Soble
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

10.  Internal jugular vein thrombosis presenting as a painful neck mass due to a spontaneous dislocated subclavian port catheter as long-term complication: a case report.

Authors:  Marcel Binnebösel; Jochen Grommes; Karsten Junge; Sonja Göbner; Volker Schumpelick; Son Truong
Journal:  Cases J       Date:  2009-06-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.